trial · primary record
VY1706 Low dose
Alzheimer s Disease
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 18 |
| Primary completion | 2029-04-28 |
| Primary endpoint | To characterize the safety and tolerability in participants with AD by Incidence of treatment emergent adverse events, changes from baseline in vital signs, physical and neurological exams and other safety measures |
| Registry ID | NCT07764146 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:07.896Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07764146
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.